Global Bacterial Vaginosis Treatment Market – Industry Trends and Forecast to 2029

Bacterial Vaginosis Treatment Market Analysis and Size

The bacterial vaginosis treatment market is expected to witness significant growth during the forecast period. Rising prevalence of vaginal infection in females worldwide and emerging markets are the factors responsible for the growth of this market. The expanding healthcare infrastructure in developing countries and the availability of generic medicine are some of the main factors driving the Bacterial Vaginosis Therapeutics Market during the forecast period. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in bacterial vaginosis treatment market in the forecast period 2022-2029. The expected CAGR of bacterial vaginosis treatment market is tend to be around 8.50% in the mentioned forecast period. The market was valued at USD 970 million in 2021, and it would grow upto USD 1862.99 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Bacterial vaginosis is the infection of vagina that happens when there's a change in the normal balance of bacteria present in the vagina. Symptom includes burning feeling, fishy smell, itching, thin white, grey, or green discharge. Females having bacterial vaginosis are at higher risk of getting other STDs. In 2001-2004 the prevalence in the United States is estimated to be 21.2 million (29.2%) among women ages 14–49, based on a nationally representative sample of women who participated in NHANES.  

Bacterial Vaginosis Treatment Market Scope and Segmentation

Global Bacterial Vaginosis Treatment Market Dynamics

Drivers

• Increased Government Initiatives

Rise in R&D activities for accurate diagnosis is likely to boost market growth. Several governments and non-government organizations, such as WHO and European Institute of Women's Health (EIWH), have undertaken great initiatives to rise awareness concerning women's health.

• Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Opportunities

• Increased Adaptation of Unhealthy Lifestyle

The rising influence of binge eating and consumption of more and more junk foods, people at times have started to neglect towards regular exercise, along with rising levels of stress, are the factors driving the market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of narcotic drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

• Lack of Awareness about the infection

The lack of awareness about these infections could curb the growth of the global bacterial vaginosis treatment market over a forecast period. Not much awareness about the infection leads to improper treatment thus restraining the market growth.

• High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This bacterial vaginosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bacterial vaginosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Bacterial Vaginosis Treatment Market            

Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.

It has been witnessed that bacterial infection during COVID-19 hospitalization was reported in approximately 6–15% of patients where it was assessed.

Global Bacterial Vaginosis Treatment Market Scope

The bacterial vaginosis treatment market is segmented on the basis of treatment, dosage form, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Medication
• Others

Dosage Form

• Creams
• Gel
• Pills
• Solution/Washes
• Injection
• Others

Route of Administration

• Oral
• Vaginal
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Bacterial Vaginosis Treatment Market Regional Analysis/Insights

The bacterial vaginosis treatment market is analysed and market size insights and trends are provided by treatment, dosage form, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the bacterial vaginosis treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for bacterial vaginosis treatment market due to presence of generic manufacturers and increased female populatio.

North America dominates the market due to increased prevalence of vaginal infections in female and affordable reimbursement scenario encourages growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Bacterial Vaginosis Treatment Market Share Analysis

The bacterial vaginosis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to bacterial vaginosis treatment market.

Key players operating in the bacterial vaginosis treatment market include:

• Pfizer Inc (U.S.)
• Mylan N.V. (U.S.)
• Novartis AG (Switzerland)
• Hikma Pharmaceuticals plc (U.K.)
• Aurobindo Pharma (India)
• AbbVie Inc. (U.S.)
• Melinta Therapeutics, Inc (U.S.)
• Bristol-Myers Squibb Company (U.S.)
• GlaxoSmithKline plc. (U.K.)
• Bayer AG (Germany)
• Lupin (India)
• Mission Pharmacal Company (U.S.)

SKU-53775